Abstract | BACKGROUND: OBJECTIVES AND METHODS: To report the disease course during pregnancy of five women who interrupted therapy with fingolimod for pregnancy. RESULTS: All patients experienced relapses during pregnancy and/or postpartum after stopping fingolimod. CONCLUSION: The risk of recurrence of disease activity during pregnancy after stopping fingolimod may be substantial. This should be considered and discussed with MS patients who are planning to become pregnant.
|
Authors | Ingrid Meinl, Joachim Havla, Reinhard Hohlfeld, Tania Kümpfel |
Journal | Multiple sclerosis (Houndmills, Basingstoke, England)
(Mult Scler)
Vol. 24
Issue 7
Pg. 991-994
(06 2018)
ISSN: 1477-0970 [Electronic] England |
PMID | 28920764
(Publication Type: Journal Article)
|
Chemical References |
- Immunosuppressive Agents
- Fingolimod Hydrochloride
|
Topics |
- Adult
- Disease Progression
- Female
- Fingolimod Hydrochloride
(therapeutic use)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy, pathology)
- Pregnancy
- Pregnancy Complications
(drug therapy, pathology)
- Recurrence
|